,trastuzumab deruxtecan
Daiichi Sankyo,AstraZeneca
['mbc', 'breast']
dr. shanu modi presents the results of db04 at #asco22. t-dxd doubled pfs and improved os vs chemo in pretreated her2-low mbc, regardless of hr expression. this is the beginning of a bright new era for breast oncology. much left to uncover on her2-low, great opportunities ahead. 
MD, Research Fellow @DanaFarber | @harvardmed | @IEOufficiale | @LaStatale. Interested in breast oncology, HER2, ADCs & good music. Coffee expert.